Current and future management of Ph/BCR-ABL positive ALL

Expert Review of Anticancer Therapy

Volumn 14, Issue 6, 2014, Pages 723-740

  Maino, Elena ^a   Sancetta, Rosaria ^a   Viero, Piera ^a   Imbergamo, Silvia ^a   Scattolin, Anna Maria ^a   Vespignani, Michele ^a   Bassan, Renato ^a  

^a OSPEDALE DELL'ANGELO   (Italy)

Author keywords

acute lymphoblastic leukemia; BCR ABL rearrangement; experimental therapy; MRD monitoring; Philadelphia chromosome; prognosis; therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BLINATUMOMAB; DASATINIB; IMATINIB; INOTUZUMAB OZOGAMICIN; NILOTINIB; PONATINIB; BENZAMIDE DERIVATIVE; MONOCLONAL ANTIBODY; NEW DRUG; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BCR ABL GENE; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER RESISTANCE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CHROMOSOME ANALYSIS; DISEASE ASSOCIATION; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; FLUORESCENCE IN SITU HYBRIDIZATION; FRAIL ELDERLY; GENE FREQUENCY; GENETIC ASSOCIATION; GERIATRIC CARE; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; CHROMOSOME ABERRATION; CLASSIFICATION; CLINICAL TRIAL (TOPIC); DISEASE MANAGEMENT; DRUG RESISTANCE; FORECASTING; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INCIDENCE; MOLECULARLY TARGETED THERAPY; ONSET AGE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENT DISEASE;

AGE OF ONSET; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; CHROMOSOME ABERRATIONS; CLINICAL TRIALS AS TOPIC; CYTOGENETIC ANALYSIS; DISEASE MANAGEMENT; DRUG RESISTANCE, NEOPLASM; DRUGS, INVESTIGATIONAL; FORECASTING; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOPHENOTYPING; INCIDENCE; MOLECULAR TARGETED THERAPY; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECURRENCE; TREATMENT OUTCOME;

EID: 84901424750     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2014.895669     Document Type: Review

References (119)

1. Kantarjian HM, Talpaz M, Dhingra K, et al. Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood 1991;78(9):2411-18
2. Cimino G, Pane F, Elia L, et al. The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: A seven-year update of the GIMEMA 0496 trial. Haematologica 2006; 91(3):377-80
3. Tabernero MD, Bortoluci AM, Alaejos I, et al. Adult precursor B-ALL with BCR/ ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expression. Leukemia 2001;15(3):406-14
4. Anastasi J, Feng J, Dickstein JI, et al. Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: Chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia. Leukemia 1996;10(5):795-802
5. Schenk TM, Keyhani A, Bottcher S, et al. Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia 1998;12(5):666-74
6. Gleissner B, Gokbuget N, Bartram CR, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: A prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002;99(5):1536-43
7. Haferlach T, Winkemann M, Ramm-Petersen L, et al. New insights into the biology of Philadelphia-chromosome-positive acute lymphoblastic leukaemia using a combination of May-Grunwald-Giemsa staining and fluorescence in situ hybridization techniques at the single cell level. Br J Haematol 1997;99(2):452-9
8. Rieder H, Ludwig WD, Gassmann W, et al. Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia. Br J Haematol 1996;95(4):678-91
9. Wetzler M, Dodge RK, Mrozek K, et al. Additional cytogenetic abnormalities in adults with Philadelphia chromosomepositive acute lymphoblastic leukaemia: A study of the Cancer and Leukaemia Group B. Br J Haematol 2004;124(3): 275-88
10. Yanada M, Takeuchi J, Sugiura I, et al. Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Haematologica 2008;93(2): 287-90
11. Rousselot P, Cayuela J-M, Recher C, et al. Dasatinib (Sprycel(R)) and chemotherapy for first-line treatment in elderly patients with de novo Philadelphia positive ALL: Results of the first 22 patients included in the EWALL-Ph-01 trial (on Behalf of the European Working Group on Adult ALL (EWALL)). ASH Annual Meeting Abstracts 2008;112(11):2920
12. Hofmann WK, de Vos S, Elashoff D, et al. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: A gene-expression study. Lancet 2002;359(9305):481-6
13. Juric D, Lacayo NJ, Ramsey MC, et al. Differential gene expression patterns and interaction networks in BCR-ABL-positive and-negative adult acute lymphoblastic leukemias. J Clin Oncol 2007;25(11): 1341-9
14. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009;360(5):470-80
15. Iacobucci I, Lonetti A, Messa F, et al. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: Implications for a new mechanism of resistance. Blood 2008; 112(9):3847-55
16. Collins-Underwood JR, Mullighan CG. Genomic profiling of high-risk acute lymphoblastic leukemia. Leukemia 2010; 24(10):1676-85
17. Ramakers-van Woerden NL, Pieters R, Hoelzer D, et al. In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: A report of the Dutch and German Leukemia Study Groups. Med Pediatr Oncol 2002;38(6):379-86
18. Rieder H, Bonwetsch C, Janssen LA, et al. High rate of chromosome abnormalities detected by fluorescence in situ hybridization using BCR and ABL probes in adult acute lymphoblastic leukemia. Leukemia 1998;12(9):1473-81
19. Maurer J, Thiel E, Ludwig W-D, et al. Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet 1991; 337(8749):1055-8
20. Radich JP, Kopecky KJ, Boldt DH, et al. Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction. Leukemia 1994; 8(10):1688-95
21. Gleissner B, Rieder H, Thiel E, et al. Prospective BCR-ABL analysis by polymerase chain reaction (RT-PCR) in adult acute B-lineage lymphoblastic leukemia: Reliability of RT-nested-PCR and comparison to cytogenetic data. Leukemia 2001;15(12):1834-40
22. Radich J, Gehly G, Lee A, et al. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 1997;89(7):2602-9
23. Scheuring UJ, Pfeifer H, Wassmann B, et al. Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) during imatinib treatment. Leukemia 2003;17(9): 1700-6
24. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: Correlations with hematologic findings outcome. A collaborative study of the Group Francais de Cytogenetique Hematologique. Blood 1996; 87(8):3135-42
25. Bassan R, Rohatiner AZ, Lerede T, et al. Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia. Hematol J 2000;1(4): 226-34
26. Faderl S, Kantarjian HM, Thomas DA, et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma 2000;36(3-4):263-73
27. Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the prospective multicenter LALA-94 trial. Blood 2002;100(7):2357-66
28. Fielding AK, Rowe JM, Richards SM, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: Results from the International ALL Trial MRC UKALLXII/ ECOG2993. Blood 2009;113(19):4489-96
29. Barrett AJ, Horowitz MM, Ash RC, et al. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1992;79(11): 3067-70
30. Chao NJ, Blume KG, Forman SJ, Snyder DS. Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1995;85(11): 3353-4
31. Snyder DS, Nademanee AP, O'Donnell MR, et al. Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. Leukemia 1999;13(12):2053-8
32. Aricò M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000;342(14):998-1006
33. Goldstone A, Prentice HG, Durrant IJ. Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL). Results from the International ALL Trial (MRC UKALLXII/ECOG E2993). Blood 2001;98:Abstract 856a
34. Esperou H, Boiron JM, Cayuela JM, et al. A potential graft-versus- leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from the French Bone Marrow Transplantation Society. Bone Marrow Transplant 2003; 31(10):909-18
35. Schrappe M, Aricò M, Harbott J, et al. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: Good initial steroid response allows early prediction of a favorable treatment outcome. Blood 1998;92(8):2730-41
36. Roy A, Bradburn M, Moorman AV, et al. Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: Results of the Medical Research Council ALL 97 trial. Br J Haematol 2005; 129(1):35-44
37. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344(14):1038-42
38. Karamlou K, Grant C, Maziarz RT. Kinetics of response to Gleevec in chronic myelogenous leukemia blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia patients. Blood 2001;98:590a
39. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002;100(6): 1965-71
40. Wassmann B, Pfeifer H, Scheuring UJ, et al. Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib. Blood 2004;103(4): 1495-8
41. Wassmann B, Pfeifer H, Scheuring U, et al. Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Leukemia 2002;16(12):2358-65
42. Rea D, Legros L, Raffoux E, et al. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia 2006;20(3):400-3
43. Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 2000;96(9): 3195-9
44. Fang G, Kim CN, Perkins CL, et al. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 2000;96(6):2246-53
45. Tipping AJ, Mahon FX, Zafirides G, et al. Drug responses of imatinib mesylate-resistant cells: Synergism of imatinib with other chemotherapeutic drugs. Leukemia 2002;16(12):2349-57
46. Topaly J, Zeller WJ, Fruehauf S. Combination therapy with imatinib mesylate (STI571): Synopsis of in vitro studies. Br J Haematol 2002;119(1):3-14
47. Lee KH, Lee JH, Choi SJ, et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2005;19(9):1509-16
48. Thomas DA, Kantarjian HM, Cortes J, et al. Outcome after frontline therapy with the hyper-CVAD and Imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL). ASH Annual Meeting Abstracts 2008;112(11):2931
49. Hatta Y, Mizuta S, Ohtake S, et al. Promising outcome of imatinib-combined chemotherapy followed by allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia: Results of the Japan Adult Leukemia Study Group (JALSG) Ph +ALL202 Regimen. ASH Annual Meeting Abstracts 2009;114(22):3090
50. Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosomepositive acute lymphoblastic leukemia: northern Italy leukemia group protocol 09/00. J Clin Oncol 2010;28(22):3644-52
51. Pfeifer H, Goekbuget N, Volp C, et al. Long-term outcome of 335 adult patients receiving different schedules of imatinib and chemotherapy as front-line treatment for Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). ASH Annual Meeting Abstracts 2010;116(21):173
52. Ribera JM, Oriol A, Gonzalez M, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica 2010; 95(1):87-95
53. Ribera JM, Garcia O, Montesinos P, et al. Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation. Br J Haematol 2012;159(1): 78-81
54. Tanguy-Schmidt A, Rousselot P, Chalandon Y, et al. Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: A GRAALL study. Biol Blood Marrow Transplant 2013;19(1): 150-5
55. Thyagu S, Minden MD, Gupta V, et al. Treatment of Philadelphia chromosomepositive acute lymphoblastic leukaemia with imatinib combined with a paediatric-based protocol. Br J Haematol 2012;158(4): 506-14
56. Chalandon Y, Thomas X, Hayette S, et al. Is less chemotherapy detrimental in adults with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) treated with high-dose imatinib? Results of the Prospective Randomized Graaph-2005 Study. ASH Annual Meeting Abstracts 2012;120(21):138
57. Fielding AK, Rowe J, Buck G, et al. UKALLXII/ECOG2993: Addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive Acute Lymphoblastic Leukaemia. Blood 2014;123(6):843-50
58. Biondi A, Schrappe M, De Lorenzo P, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): A randomised, open-label, intergroup study. Lancet Oncol 2012;13(9):936-45
59. Vignetti M, Fazi P, Cimino G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: Results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood 2007;109(9):3676-8
60. Ottmann OG, Wassmann B, Pfeifer H, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer 2007;109(10):2068-76
61. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354(24):2531-41
62. Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: Interim results of a phase 2 study. Blood 2007;110(7): 2309-15
63. Quintas-Cardama A, Kantarjian H, Cortes J. Tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 2007;357(15):1557; author reply 1557-1558
64. Foà R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosoma positive acute lymphoblastic leukemia. Blood 2011;118(25):6521-8
65. Ravandi F, O'Brien S, Garris R, et al. Final report of single-center study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphiachromosome positive acute lymphoblastic leukemia. ASH Annual Meeting Abstracts 2013;In press
66. Kim DY, Don Joo Y, Kim SD, Lee KH. Nilotinib combined with multi-agent chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive Acute Lymphoblastic Leukemia: Final results of prospective multicenter phase 2 study. ASH Annual Meeting Abstracts 2013;In press
67. Ribera JM. Optimal approach to treatment of patients with Philadelphia chromosomepositive acute lymphoblastic leukemia: How to best use all the available tools. Leuk Lymphoma 2013;54(1):21-7 Excellent recent review article.
68. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012;367(22):2075-88
69. Jabbour E, Kantarjian H, Thomas D, et al. Phase II study of combination of Hyper-CVAD with Ponatinib in front line therapy of patients (pts) with Philadelphia chromosome (Ph) positive Acute Lymphoblastic Leukemia (ALL). J Clin Oncol 2013;31(Suppl):Abstract 7024
70. Mitterbauer G, Nemeth P, Wacha S, et al. Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction. Br J Haematol 1999;106(3):634-43
71. Pane F, Cimino G, Izzo B, et al. Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. Leukemia 2005; 19(4):628-35
72. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103(12):4396-407
73. Wassmann B, Pfeifer H, Stadler M, et al. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2005;106(2):458-63
74. Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006;108(5):1469-77
75. Lee S, Kim YJ, Chung NG, et al. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 2009;115(3):561-70
76. Ravandi F, O'Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 2010; 116(12):2070-7
77. Lee S, Kim DW, Cho BS, et al. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosomepositive acute lymphoblastic leukemia. Leukemia 2012;26(11):2367-74
78. Rousselot P, Coude MM, Huguet F, et al. Dasatinib (Sprycel(R)) and low intensity chemotherapy for first-line treatment in patients with de novo Philadelphia positive ALL aged 55 and over: Final results of the EWALL-Ph-01 Study. ASH Annual Meeting Abstracts 2012;120(21):666
79. Ravandi F, Jorgensen JL, Thomas DA, et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood 2013;122(7):1214-21
80. Spinelli O, Peruta B, Tosi M, et al. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica 2007;92(5): 612-18
81. Pfeifer H, Wassmann B, Pavlova A, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2007;110(2):727-34
82. Soverini S, Vitale A, Poerio A, et al. Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. Haematologica 2011; 96(4):552-7
83. Pfeifer H, Lange T, Wystub S, et al. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia. Leukemia 2012;26(7):1475-81
84. Jones D, Thomas D, Yin CC, et al. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer 2008; 113(5):985-94
85. Mizuta S, Matsuo K, Yagasaki F, et al. Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia. Leukemia 2011;25(1):41-7
86. Mohty M, Labopin M, Volin L, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: A retrospective study from the European Group for Blood and Marrow Transplantation. Blood 2010; 116(22):4439-43
87. Ram R, Storb R, Sandmaier BM, et al. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica 2011;96(8):1113-20
88. Nicolini FE, Basak GW, Soverini S, et al. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood 2011;118(20): 5697-700
89. Benjamini O, Kantarjian H, O'Brien S, et al. Combination chemotherapy with tyrosine kinase inhibitors can overcome Bcr-Abl mutation in acute lymhoblastic leukemia or blast crisis CML. ASH Annual Meeting Abstracts 2013;In press
90. Shimoni A, Kroger N, Zander AR, et al. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphiapositive acute leukemias. Leukemia 2003; 17(2):290-7
91. Pfeifer H, Wassmann B, Bethge W, et al. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia 2013;27(6):1254-62
92. Carella AM, Frassoni F, Pollicardo N, et al. Philadelphia-chromosome- negative peripheral blood stem cells can be mobilized in the early phase of recovery after a myelosuppressive chemotherapy in Philadelphia-chromosome- positive acute lymphoblastic leukaemia. Br J Haematol 1995;89(3):535-8
93. Atta J, Martin H, Bruecher J, et al. Residual leukemia and immunomagnetic bead purging in patients with BCR-ABL-positive acute lymphoblastic leukemia. Bone Marrow Transplant 1996;18(3):541-8
94. Mizuta S, Kohno A, Morishita Y, et al. Long-term follow-up of 14 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia following autologous bone marrow transplantation in first complete remission. Int J Hematol 2007;85(2):140-5
95. Giebel S, Labopin M, Gorin NC, et al. Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: A report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Eur J Cancer 2014;50(2): 411-17
96. Wetzler M, Watson D, Stock W, et al. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation-results of CALGB Study 10001 (Alliance). Haematologica 2014;99(1):111-15
97. Pfeifer H, Wystub S, Binckebanck A, et al. Imatinib (IM) and interferon-alpha (IFN-a) maintenance therapy is associated with long-term DFS in a subset of elderly patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). ASH Annual Meeting Abstracts 2012;120(21): 1503
98. Pfeifer H, Wettner C, Wassmann B, et al. Long term follow-up of 121 elderly patients with Philadelphia-positive acute lymphoblastic leukaemia (Ph+ALL) treated in prospective GMALL trials supports a greater emphasis on allogeneic SCT as definitive postremission therapy. ASH Annual Meeting Abstracts 2012;120:21-2608
99. Delannoy A, Delabesse E, Lheritier V, et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: Results of the GRAALL AFR09 study. Leukemia 2006; 20(9):1526-32
100. Papayannidis C, Fazi P, Piciocchi A, et al. Treating Ph+ acute lymphoblastic leukemia (ALL) in the elderly: The sequence of two tyrosine kinase Inhibitors (TKI) (Nilotinib and Imatinib) does not prevent mutations and relapse. ASH Annual Meeting Abstracts 2012;120(21):2601
101. Pfeifer H, Wassmann B, Hofmann WK, et al. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res 2003;9(13): 4674-81
102. Takayama N, Sato N, O'Brien SG, et al. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosomepositive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol 2002;119(1):106-8
103. Patel SB, Gojo I, Tidwell ML, et al. Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy. Leuk Lymphoma 2011;52(7):1211-14
104. Bassan R. Optimal central nervous system prophylaxis in Philadelphia chromosomepositive acute lymphoblastic leukemia: Collateral damage in the imatinib era? Leuk Lymphoma 2011;52(7):1164-5
105. Gokbuget N, Hartog CM, Bassan R, et al. Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma. Haematologica 2011;96(2):238-44
106. Porkka K, Koskenvesa P, Lundan T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosomepositive leukemia. Blood 2008;112(4): 1005-12
107. Bhojwani D, Pui CH. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol 2013;14(6):e205-17
108. Giles FJ, le Coutre PD, Pinilla-Ibarz J, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 2013;27(1):107-12
109. Katagiri S, Tauchi T, Okabe S, et al. Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia. Clin Cancer Res 2013;19(6):1422-32
110. Riva G, Luppi M, Barozzi P, et al. Emergence of BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during long-term imatinib mesylate treatment. Blood 2010;115(8):1512-18
111. Hoelzer D, Gokbuget N. Chemoimmunotherapy in acute lymphoblastic leukemia. Blood Rev 2012; 26(1):25-32
112. Kantarjian H, Thomas D, Wayne AS, O'Brien S. Monoclonal antibody-based therapies: A new dawn in the treatment of acute lymphoblastic leukemia. J Clin Oncol 2012;30(31):3876-83
113. Bassan R, Scattolin AM, Maino E, et al. Monoclonal antibody therapy of adult acute lymphoblastic leukemia: Progress and challenge for new clinical trials. Drugs Cell Ther Hematol 2013;1(1):5-20
114. Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 2013;119(15):2728-36
115. Topp MS, Gokbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012;120(26): 5185-7
116. Topp MS, Goekbuget N, Zugmaier G, et al. Anti-CD19 BiTE blinatumomab induces high complete remission rate and prolongs overall survival in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). ASH Annual Meeting Abstracts 2012;120(21):670
117. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5(177): 177ra138
118. Haso W, Lee DW, Shah NN, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 2012;121(7):1165-74
119. Cruz CR, Micklethwaite KP, Savoldo B, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: A phase 1 study. Blood 2013;122(17):2965-73